Amarin Corporation PLC at Citi Biotech Conference Transcript
Thank you for joining us. As you know, I'm Joel Beatty, one of the Citi's biotech analyst. And I'm pleased to have with me John Thero, CEO of Amarin.
Questions & Answers
So let's get started with -- talking about Europe, for Amarin, given that the EFC cardiology conference just wrapped up over the last few days. I mean, I think -- and one thing that came out it is new guidelines and Europe recommends the use of Vascepa in patients with triglycerides 135 and up. Can you talk a little bit about the development for that for Amarin in Vascepa?
Sure. I mean, before I get started here, I will, through my comments, be making forward-looking statements. And there are risks associated with all forward-looking statements, and I suggest that investors review our SEC filings and risk factors before
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |